CYTK – Cytokinetics, Incorporated
Cytokinetics, IncorporatedCYTK
$60.82Name : Cytokinetics, Incorporated
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $7,277,548,032.00
EPSttm : -5.12
Cytokinetics, Incorporated
$60.82
1.08%$0.65Float Short %
12.18
Margin Of Safety %
Put/Call OI Ratio
0.21
EPS Next Q Diff
-0.46
EPS Last/This Y
-0.36
EPS This/Next Y
-0.13
Price
60.18
Target Price
75.5
Analyst Recom
1.43
Performance Q
64.29
Relative Volume
0.83
Beta
0.58
Ticker: CYTK
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | CYTK | 52.08 | 0.20 | 0.55 | 90653 |
| 2025-09-09 | CYTK | 51.47 | 0.20 | 0.74 | 91166 |
| 2025-09-10 | CYTK | 52.02 | 0.20 | 0.17 | 91648 |
| 2025-09-11 | CYTK | 53.19 | 0.20 | 0.23 | 91892 |
| 2025-09-12 | CYTK | 51.25 | 0.20 | 0.24 | 92171 |
| 2025-09-15 | CYTK | 49.46 | 0.20 | 0.51 | 92883 |
| 2025-09-16 | CYTK | 49.75 | 0.20 | 0.07 | 94020 |
| 2025-09-17 | CYTK | 47.56 | 0.20151628484856 | 0.057463925424595 | 94772 |
| 2025-09-18 | CYTK | 49.32 | 0.19 | 0.05 | 99728 |
| 2025-09-22 | CYTK | 48.24 | 0.17 | 0.10 | 83141 |
| 2025-09-23 | CYTK | 48.56 | 0.17 | 2.64 | 84334 |
| 2025-09-24 | CYTK | 48.29 | 0.20 | 0.67 | 86172 |
| 2025-09-25 | CYTK | 47.89 | 0.21 | 0.42 | 86590 |
| 2025-09-26 | CYTK | 50.42 | 0.21 | 0.91 | 86896 |
| 2025-09-29 | CYTK | 53.89 | 0.21 | 0.01 | 87218 |
| 2025-09-30 | CYTK | 54.99 | 0.18 | 1.14 | 100479 |
| 2025-10-01 | CYTK | 55.86 | 0.20 | 0.30 | 103175 |
| 2025-10-02 | CYTK | 56.32 | 0.21 | 0.29 | 103341 |
| 2025-10-03 | CYTK | 56.96 | 0.21 | 0.15 | 103284 |
| 2025-10-06 | CYTK | 60.66 | 0.21 | 0.04 | 103711 |
| 2025-10-07 | CYTK | 60.21 | 0.21 | 0.08 | 106533 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | CYTK | 52.09 | -15.5 | -94.8 | -5.62 |
| 2025-09-09 | CYTK | 51.56 | -15.5 | -99.1 | -5.62 |
| 2025-09-10 | CYTK | 52.01 | -15.5 | -111.6 | -5.62 |
| 2025-09-11 | CYTK | 53.32 | -15.5 | -121.2 | -5.62 |
| 2025-09-12 | CYTK | 51.10 | -15.5 | -79.7 | -5.62 |
| 2025-09-15 | CYTK | 49.47 | -15.5 | -85.4 | -5.62 |
| 2025-09-16 | CYTK | 49.76 | -15.5 | -109.5 | -5.62 |
| 2025-09-17 | CYTK | 47.55 | -15.5 | -78.0 | -5.62 |
| 2025-09-18 | CYTK | 49.33 | -15.5 | -128.5 | -5.62 |
| 2025-09-19 | CYTK | 48.62 | -15.5 | -97.0 | -5.62 |
| 2025-09-22 | CYTK | 48.25 | -15.5 | -101.2 | -5.62 |
| 2025-09-23 | CYTK | 48.60 | -15.5 | -109.9 | -5.62 |
| 2025-09-24 | CYTK | 48.28 | -15.5 | -102.1 | -5.62 |
| 2025-09-25 | CYTK | 47.83 | -15.5 | -99.6 | -5.62 |
| 2025-09-26 | CYTK | 50.40 | -15.5 | -138.8 | -5.62 |
| 2025-09-29 | CYTK | 53.84 | -15.5 | -147.8 | -5.62 |
| 2025-09-30 | CYTK | 54.99 | -15.5 | -118.2 | -5.62 |
| 2025-10-01 | CYTK | 55.86 | -15.5 | -115.6 | -5.62 |
| 2025-10-02 | CYTK | 56.27 | -15.5 | -110.2 | -5.62 |
| 2025-10-03 | CYTK | 56.96 | -15.4 | -112.6 | -5.62 |
| 2025-10-06 | CYTK | 60.67 | -15.4 | -153.3 | -5.62 |
| 2025-10-07 | CYTK | 60.18 | -15.4 | -100.8 | -5.62 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | CYTK | -8.06 | 2.25 | 13.10 |
| 2025-09-09 | CYTK | -8.09 | 2.25 | 13.10 |
| 2025-09-10 | CYTK | -8.15 | 2.25 | 13.10 |
| 2025-09-11 | CYTK | -8.15 | 2.25 | 11.82 |
| 2025-09-12 | CYTK | -8.15 | 2.25 | 11.82 |
| 2025-09-15 | CYTK | -7.45 | 2.25 | 11.82 |
| 2025-09-16 | CYTK | -7.45 | 2.25 | 11.82 |
| 2025-09-17 | CYTK | -7.45 | 2.25 | 11.82 |
| 2025-09-18 | CYTK | -5.27 | 2.25 | 11.82 |
| 2025-09-19 | CYTK | -5.20 | 2.25 | 11.82 |
| 2025-09-22 | CYTK | -5.20 | 2.25 | 11.82 |
| 2025-09-23 | CYTK | -5.23 | 2.25 | 11.82 |
| 2025-09-24 | CYTK | -5.30 | 2.25 | 11.82 |
| 2025-09-25 | CYTK | -5.30 | 2.25 | 12.18 |
| 2025-09-26 | CYTK | -5.30 | 2.25 | 12.18 |
| 2025-09-29 | CYTK | -5.30 | 2.28 | 12.18 |
| 2025-09-30 | CYTK | -5.52 | 2.28 | 12.18 |
| 2025-10-01 | CYTK | -5.18 | 2.28 | 12.18 |
| 2025-10-02 | CYTK | -5.18 | 2.28 | 12.18 |
| 2025-10-03 | CYTK | -5.18 | 2.28 | 12.18 |
| 2025-10-06 | CYTK | -5.40 | 2.28 | 12.18 |
| 2025-10-07 | CYTK | -5.42 | 2.28 | 12.18 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.12
Avg. EPS Est. Current Quarter
-1.57
Avg. EPS Est. Next Quarter
-1.58
Insider Transactions
-5.42
Institutional Transactions
2.28
Beta
0.58
Average Sales Estimate Current Quarter
6
Average Sales Estimate Next Quarter
9
Fair Value
Quality Score
8
Growth Score
41
Sentiment Score
97
Actual DrawDown %
45.4
Max Drawdown 5-Year %
-72.4
Target Price
75.5
P/E
Forward P/E
PEG
P/S
83.97
P/B
P/Free Cash Flow
EPS
-5.12
Average EPS Est. Cur. Y
-5.62
EPS Next Y. (Est.)
-5.75
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-707.17
Relative Volume
0.83
Return on Equity vs Sector %
139.2
Return on Equity vs Industry %
152.9
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.05
EBIT Estimation
-100.8
Cytokinetics, IncorporatedSector: Healthcare
Industry: Biotechnology
Employees: 498
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
stock quote shares CYTK – Cytokinetics, Incorporated Stock Price stock today
news today CYTK – Cytokinetics, Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch CYTK – Cytokinetics, Incorporated yahoo finance google finance
stock history CYTK – Cytokinetics, Incorporated invest stock market
stock prices CYTK premarket after hours
ticker CYTK fair value insiders trading